• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioAtla Inc. (Amendment)

    2/9/24 4:58:18 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    SC 13G/A 1 bioatla-jayshort_13ga.htm BIOATLA, INC. JAY SHORT 13G/A





    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
    BioAtla, Inc.
    (Name of Issuer)
     
     
     
    Common Stock, par value $0.0001
    (Title of Class of Securities)
     
     
     
    09077B104
    (CUSIP Number)
     
     
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
     
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. 

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    SCHEDULE 13G
    CUSIP No. 09077B104
     

    1
    NAMES OF REPORTING PERSONS
       
    Jay M. Short
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
       
    3
    SEC USE ONLY
       
         
       
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
    United States of America
       
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
       
    2,103,542 (includes 405,532 shares underlying options that are exercisable within 60 days of December 31, 2023)
       
       
    6
    SHARED VOTING POWER
       
    1,354,648 (of which 1,354,598 shares are owned or controlled by Dr. Short’s spouse as to which he disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any)
       
       
    7
    SOLE DISPOSITIVE POWER
       
    2,103,542 (includes 405,532 shares underlying options that are exercisable within 60 days of December 31, 2023)
       
       
    8
    SHARED DISPOSITIVE POWER
       
    1,354,648 (of which 1,354,598 shares are owned or controlled by Dr. Short’s spouse as to which he disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any)
       
       
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    3,458,190
       
       
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    ☐
       
       
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    7.2%
       
       
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    IN
       
       

    CUSIP No. 09077B104
     

    1
    NAMES OF REPORTING PERSONS
       
    Himalaya Parent LLC
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
       
    3
    SEC USE ONLY
       
         
       
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
    Delaware
       
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
       
    ‑ 0 ‑
       
       
    6
    SHARED VOTING POWER
       
    50
       
       
    7
    SOLE DISPOSITIVE POWER
       
    ‑ 0 ‑
       
       
    8
    SHARED DISPOSITIVE POWER
       
    50
       
       
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    50
       
       
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    ☐
       
       
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    0.0%
       
       
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    OO – limited liability company
       


    Item 1(a).
    Name of Issuer:
      BioAtla, Inc.

       
    Item 1(b).
    Address of Issuer's Principal Executive Offices:
      11085 Torreyana Road, San Diego, California 92121

       
    Item 2(a).
    Name of Person Filing:
     
    (1)  Jay M. Short
    (2) Himalaya Parent LLC
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:
    (1) Jay M. Short
    c/o BioAtla, Inc.
    11085 Torreyana Road
    San Diego, California 92121
    (2) Himalaya Parent LLC
    c/o BioAtla, Inc.
    11085 Torreyana Road
    San Diego, California 92121
    Item 2(c).
    Citizenship:
    (1)  Jay M. Short: United States of America
    (2) Himalaya Parent LLC: Delaware
       
    Item 2(d).
    Title of Class of Securities:
      Common Stock, par value $0.0001

       
    Item 2(e).
    CUSIP Number:
      09077B104

       
    Item 3.
    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
      240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

     
    (a)
    ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
    (e)
    ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
     
    (f)
    ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
     
    (g)
    ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
     
    (h)
    ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
     
    (k)
    ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable.
    Item 4.
    Ownership.
     
    (a)
    Amount beneficially owned:
       
    (1) Jay M. Short: 3,458,190
    (2) Himalaya Parent LLC: 50


    (1) As of the date hereof, Dr. Short beneficially owns 3,458,190 shares of common stock of the Issuer. This amount includes: (i) 1,844,815 shares held by Dr. Short, which includes 405,532 shares of common stock that are issuable upon exercise of outstanding options within sixty days of December 31, 2023; (ii) 258,727 shares held by Jay Short 2020 Irrevocable Gift Trust, which Dr. Short is the trustee of and holds sole voting and dispositive power with respect to the shares; (iii) 793,547 shares held by Carolyn Anderson Short, Dr. Short’s spouse, as to which Dr. Short disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any; (iv) 258,727 shares held by Carolyn Short 2020 Irrevocable Gift Trust, as to which Dr. Short disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any; (v) 302,324 shares held by Capia IP, LLC, which Carolyn Anderson Short is the managing member of and as to which Dr. Short disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any; and (vi) 50 shares held by Himalaya Parent LLC, which Dr. Short and Carolyn Anderson Short are the managers of and as to which Dr. Short and Carolyn Anderson Short disclaim beneficial ownership of except to the extent of his or her pecuniary interest therein.





    Dr. Short is the Co-founder, Chairman and Chief Executive Officer of the Issuer and Ms. Anderson Short is Dr. Short’s spouse.
     
    (b)
    Percent of class:
       
    (1) Jay M. Short: 7.2%
    (2) Himalaya Parent LLC: 0.0%
         
        The above percentages are calculated in accordance with Rule 13d-3 based on 48,077,599 issued and outstanding shares of common stock of the Issuer as of December 31, 2023.

     
    (c)
    Number of shares as to which the person has:
     
    (i)
    Sole power to vote or to direct the vote:
       
    (1)Jay M. Short: 2,103,542
    (2)Himalaya Parent LLC: 0

     
    (ii)
    Shared power to vote or to direct the vote:
       
    (1)Jay M. Short: 1,354,648
    (2)Himalaya Parent LLC: 50

     
    (iii)
    Sole power to dispose or to direct the disposition of:
       
    (1)Jay M. Short: 2,103,542
    (2)Himalaya Parent LLC: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of:
       
    (1)Jay M. Short: 1,354,648
    (2)Himalaya Parent LLC: 50

       
    Item 5.
    Ownership of Five Percent or Less of a Class.
    Not applicable.
       
    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not applicable.
       
    Item 8.
    Identification and Classification of Members of the Group.
    Not applicable.
       
    Item 9.
    Notice of Dissolution of Group.
    Not applicable.
       
    Item 10.
    Certification.
     
    (a) Not applicable.
    (b) Not applicable.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

       
       
         
    Dated: February 9, 2024
    Jay M. Short
       
     
    By:
     /s/ Jay M. Short
       
    Name: Jay M. Short
     
     
         
       
    Dated: February 9, 2024
    Himalaya Parent LLC
       
     
    By:
     /s/ Jay M. Short
       
    Name: Jay M. Short
    Title:   Manager
     
     










    Get the next $BCAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    8/13/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

    FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next yearCompany maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of so

    9/8/25 8:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

    CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management to host conference call and webcast today at 4:30 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology co

    8/7/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

    SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Thursday, August 7, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Second Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 274-8461 (domestic), (203) 518-9814 (internation

    8/4/25 8:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    1/19/24 4:21:50 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/26/23 7:43:02 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/20/23 6:27:44 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 6,347 shares, decreasing direct ownership by 0.28% to 2,243,678 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    9/2/25 7:09:06 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Vasquez Christian covered exercise/tax liability with 1,566 shares, decreasing direct ownership by 0.55% to 283,564 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    9/2/25 7:08:38 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Sievers Eric covered exercise/tax liability with 2,729 shares, decreasing direct ownership by 0.74% to 364,574 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    9/2/25 7:08:14 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    SEC Filings

    View All

    SEC Form 10-Q filed by BioAtla Inc.

    10-Q - BioAtla, Inc. (0001826892) (Filer)

    8/7/25 5:01:11 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BioAtla, Inc. (0001826892) (Filer)

    8/7/25 4:06:58 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - BioAtla, Inc. (0001826892) (Filer)

    6/20/25 4:06:53 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioAtla downgraded by Citizens JMP

    Citizens JMP downgraded BioAtla from Mkt Outperform to Mkt Perform

    8/13/25 8:01:09 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla downgraded by H.C. Wainwright

    H.C. Wainwright downgraded BioAtla from Buy to Neutral

    11/13/24 7:31:56 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    JMP Securities initiated coverage on BioAtla with a new price target

    JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00

    9/15/22 7:31:28 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    View All

    BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

    SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

    12/21/21 9:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

    SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

    11/14/24 4:00:05 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

    SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

    10/2/24 4:30:04 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

    SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

    9/6/24 4:59:38 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Financials

    Live finance-specific insights

    View All

    BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

    CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management to host conference call and webcast today at 4:30 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology co

    8/7/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

    SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Thursday, August 7, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Second Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 274-8461 (domestic), (203) 518-9814 (internation

    8/4/25 8:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

    CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

    5/6/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care